Inflammopharmacology 14 , 214221
Reduced tiredness and fatigue
No studies have been performed to determine safety of GLP-1s in patients who are pregnant or breastfeeding
Why This Three-Entity Structure Matters This separation is legally required to ensure that: Platform companies don't practice medicine without a license - Technology platforms cannot make clinical decisions Clinical independence is preserved - Prescribers must make medical judgments free from commercial pressure Pharmacy regulations are followed - Medication dispensing must comply with state and federal pharmacy laws For you as a patient, this means: You're not getting medical care "from Elevate Health" - you're getting it from independent providers who use Elevate Health's platform The platform coordinates the process but doesn't control whether you get a prescription If there's a clinical question or medication issue, you'll interact with the provider or pharmacy, not just the platform's customer service team This three-entity structure is common across telehealth platforms and ensures appropriate separation between the technology platform, clinical decision-making, and medication dispensing
Thus, the exception: the patient with chronic soft-tissue damage, inflammation or whos in the midst of post-injury repair
Most patients see more significant results after 8-12 weeks as the dosage is gradually increased
